Biomarker Guided Treatment in Gynaecological Cancer
Recruiting now · Phase 4
Conditions studied: Endometrial Cancer
In brief
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
Key facts
- Study ID
- NCT02543710
- Run by
- Haukeland University Hospital
- People needed
- 1300
- Starts
- 2015-10-01
- Expected to finish
- 2033-12-01
- Last updated by the study team
- 2017-03-28
Who can join
Age: 18 and older, up to 95. Sex: female. Healthy volunteers: not accepted.
Where it is running
- St Olav university hospital — Trondheim, Norway (enrolling)
- Spsk No 1 — Lublin, Poland (enrolling)
- Ålesund hospital — Ålesund, Norway (enrolling)
- Førde central hospital — Førde, Norway (enrolling)
- Women's hospital, Haukeland university hospital — Bergen, Hordaland, Norway (enrolling)
- Akershus University hospital — Oslo, Norway (enrolling)
- Stavanger university hospital — Stavanger, Norway (enrolling)
- Sørlandet hospital — Kristiansand, Norway
- Radboud university hospital — Nijmegen, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.